Displaying drugs 15076 - 15100 of 15372 in total
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
2,5-Dimethoxy-4-(n)-propylthiophenethylamine
Experimental
Illicit
Embutramide
Experimental
Illicit
4-Bromo-2,5-dimethoxyphenethylamine
Experimental
Illicit
SC-74020
Experimental
N-Cyclohexyl-N'-(4-Iodophenyl)Urea
Experimental
N-Butyl-Benzenesulfonamide
Experimental
3,5-Difluorobenzenesulfonamide
Experimental
4-iodo-acetamido phenylboronic acid
Experimental
PASBN
Experimental
4-Phenylbutylamine
Experimental
2,3-Difluorobenzyl Alcohol
Experimental
Phenethylamine
Experimental
Soneclosan
Experimental
3-Phenylpropylamine
Experimental
2,5-di-tert-butylhydroquinone
Experimental
(S)-4-Nitrostyrene oxide
Experimental
Displaying drugs 15076 - 15100 of 15372 in total